Susquehanna Fundamental Investments LLC Acquires Shares of 39,093 Tyra Biosciences, Inc. (NASDAQ:TYRA)

Susquehanna Fundamental Investments LLC bought a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 4th quarter, HoldingsChannel reports. The fund bought 39,093 shares of the company’s stock, valued at approximately $543,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in TYRA. Alta Partners Management Company L.P. purchased a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $56,716,000. Pictet Asset Management Holding SA purchased a new stake in Tyra Biosciences in the 4th quarter valued at about $4,921,000. Investment Counsel Co. of Nevada bought a new position in shares of Tyra Biosciences during the 4th quarter worth approximately $1,182,000. Raymond James Financial Inc. purchased a new position in shares of Tyra Biosciences in the 4th quarter worth approximately $761,000. Finally, Marshall Wace LLP grew its holdings in shares of Tyra Biosciences by 175.7% in the fourth quarter. Marshall Wace LLP now owns 54,077 shares of the company’s stock valued at $752,000 after acquiring an additional 34,463 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Insider Activity at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 5,401 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the transaction, the director now directly owns 443,885 shares of the company’s stock, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 15.40% of the stock is owned by company insiders.

Tyra Biosciences Stock Performance

TYRA stock opened at $10.86 on Friday. The stock has a fifty day moving average of $9.80 and a 200-day moving average of $13.82. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The company has a market capitalization of $576.56 million, a price-to-earnings ratio of -6.75 and a beta of 1.19.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. Equities analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. UBS Group started coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.